Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.

Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, Weder P, Zander T, Wick W, Weller M. Acta Oncol. 2011 Jun,50(5):630-5. doi: 10.3109/0284186X.2011.572913. Epub 2011 Apr 18.

Zoledronic acid for adjuvant use in patients with breast cancer.

Ressler S, Mlineritsch B, Greil R. Expert Rev Anticancer Ther. 2011 Mar,11(3):333-49. doi: 10.1586/era.11.13.

ASH Report. Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010.

Melchardt T, Hofbauer SW, Greil R, Hopfinger G. Memo – Magazine of European Medical Oncology. 2011 June 1, 4(2): 120-123.

Riding the 2-edged sword.

Egle A. Blood. 2010 Jun 3,115(22):4325-6. doi: 10.1182/blood-2010-03-272211.

CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B.

Leick M, Catusse J, Follo M, Nibbs RJ, Hartmann TN, Veelken H, Burger M. mmunology. 2010 Apr,129(4):536-46. doi: 10.1111/j.1365-2567.2009.03209.x. Epub 2009 Dec 2.

ÖGHO-Frühjahrstagung: Chronische Lymphatische Leukämie, Adhäsionsmoleküle als mögliche therapeutische Ziele.

Hartmann TN. JATROS Haematologie und Onkologie. 3/2010, Seite 63-65.

Erforschung der Chronisch Lymphatischen Leukämie am LIMCR.

Hartmann TN. Med.ium. 6/2010.

Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.

Weiss L, Melchardt T, Neureiter D, Kemmerling R, Moshir S, Pleyer L, Greil R, Egle A. J Clin Oncol. 2011 Aug 20,29(24):e696-8. doi: 10.1200/JCO.2011.35.8283. Epub 2011 Jul 5.

Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Engert, A, Borchmann, P, Pluetschow, A, von Tresckow, B, Markova, J, Hitz, F, Kral, Z, Greil, R, Topp, MS, Villalobos, M, Zijlstra, JM, Soekler, M, Stein, H, Eich, HT, Mueller, RP, Fuchs, M, Diehl, V BLOOD. 2010, 116(21): 336-336.

Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC)

Steger, GG, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Rudas, M, Marth, C, Stoeger, H, Singer, CF, Gnant, M EJC SUPPL. 2010, 8(3): 60-60.